ProPhase Labs, Inc. (NASDAQ:PRPH) Sees Large Increase in Short Interest

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 245,700 shares, an increase of 59.4% from the October 31st total of 154,100 shares. Based on an average daily trading volume, of 114,300 shares, the short-interest ratio is presently 2.1 days.

ProPhase Labs Trading Down 0.8 %

PRPH stock traded down $0.01 during midday trading on Friday, reaching $0.76. The company’s stock had a trading volume of 2,922 shares, compared to its average volume of 60,997. The business’s 50-day simple moving average is $1.83 and its 200-day simple moving average is $2.99. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a 52 week low of $0.66 and a 52 week high of $7.48. The stock has a market cap of $18.24 million, a PE ratio of -0.61 and a beta of -0.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PRPH. Geode Capital Management LLC boosted its stake in ProPhase Labs by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after acquiring an additional 13,590 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of ProPhase Labs by 18.3% during the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after buying an additional 27,673 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in ProPhase Labs by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock valued at $4,003,000 after buying an additional 9,416 shares during the last quarter. 9.45% of the stock is currently owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.